Nanobiotix Starts a New Research Program, in Immuno Oncology

Screen Shot 2016-01-05 at 10.31.19 pm.png

Small but heading for the big time

NANOBIOTIX, a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces today that, in addition to its current advanced clinical development program, the Company has started exploring the use of NBTXR3 for combination in Immuno Oncology.

Elsa Borghi, Nanobiotix’s Medical Director, commented: “With six ongoing indications, our global clinical development of NBTXR3 as a radio-enhancer, is progressing well. This Immuno Oncology program could bring new applications and confirm that additional patient populations could benefit from treatment with NBTXR3”.

NBTXR3 is a radio-enhancer, using a physical mode of action to destroy cancer cells in any solid tumors, in combination with radiotherapy.

Nanobiotix is running a global clinical development program with its lead product NBTXR3, in six indications across Europe, the US and the Asia-Pacific Region: a registration trial in soft tissue sarcoma, and Phase I/II trials in liver cancers (HCC and liver metastases), prostate cancer, head and neck cancer and rectal cancer (in Asia by Nanobiotix’s partner PharmaEngine).

In situ (intratumoral) vaccination with NBTXR3 opens new potential prospects in Immuno Oncology.

The aim of Immuno Oncology (IO) is to boost patients’ immune systems to fight cancer, through different approaches. It is very efficient for a limited number of patients whose tumors have natural and sufficient immunogenicity. However, to exploit the full potential of immune therapies it is necessary to increase this immunogenicity at tumor level.

Indeed, it has been demonstrated that radiotherapy can be used to improve immunogenicity, by creating Immunogenic Cell Death (ICD) in many situations.

NBTXR3 nanoparticles’ activation enhances the energy deposited where they are injected, improving the cancer cell death and efficacy of radiotherapy. This technology is based on physics and can potentially be applied across all radiotherapy indications. All preclinical model have shown a systematic superiority of cell killing, when using NBTXR3 with radiotherapy, compared to radiotherapy alone.

Hence, NBTXR3 could have the potential to be used as an in situ (intratumoral) vaccination that would create ICDs which, in turn, could bring a new dimension and broaden the usage of immuno therapies in oncology.

To explore this brand new field of development opportunities, the Company has launched a pre-clinical development program.

About NANOBIOTIX: www.nanobiotix.com

Source: ACNNewswire.

1 reply

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s